can be explained in view of lorlatinib used in those with extensive disease progressed on multiple lines of therapy and ongoing responses [ Table 3 ].
We report clinical outcomes on patients with crizotinib-resistant disease treated with lorlatinib and find it an important new treatment option for those patients whose disease has progressed after treatment with crizotinib or second-generation ALK tyrosine kinase inhibitors.
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Letter to the Editor T a m o x i f e n a n d f u l v e s t r a n t i n d u c e d steatohepatitis with cirrhosis: A rare case report DOI: 10 .4103/sajc.sajc_132_19
Dear Editor, Tamoxifen has improved the survival of patients with breast cancer. One of the less-recognized side effects is hepatic steatosis in 30%-40% of patients diagnosed on radiology, which progresses in 1%-2% to steatohepatitis and rarely to cirrhosis. Fulvestrant-induced acute hepatotoxicity has rarely been reported in literature. [1] Tamoxifen has also rarely been associated with cirrhosis and submassive hepatic necrosis. [2, 3] A 58-year-old postmenopausal female with well-controlled diabetes, hypertension, hypothyroidism, and body mass index of 26 kg/m 2 was diagnosed with right locally advanced breast cancer in August 2007. The histopathology showed the presence of invasive ductal carcinoma, Grade III, and it was strongly positive for the estrogen and progesterone receptors. She underwent modified radical mastectomy and subsequently was treated with adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel sequentially followed (Continue on page 228...) revealed additional lesions on NBI; however, only seven of these were biopsied and four were confirmed to be malignant. [18] We have presented our initial experience with NBI at a tertiary institute from India. The study shows an improved lesion detection rate, however, in lieu of high false-positive rate. The study cohort is small, and the population is mixed; however, we want to emphasize that various lesions, including normal transitional epithelium, can also mimic malignancy on NBI leading to unnecessary biopsies. In addition, NMIBC requires long follow-ups and repeated cystoscopic evaluation adding to the burden. This could be a major impediment to a resource-limited country like ours. We plan to prospectively follow the patients to evaluate the impact on recurrence rates. NBI ushers a new era of technological advancement with improved detection rates; however, it is fraught with limited availability, high false-positivity, learning curve, limited benefit, and the paucity of the literature. It requires further scrutiny by long-term follow-up studies before being introduced into routine clinical practice.
Conclusion
The inclusion of NBI to conventional white light TURBT increases the sensitivity for identifying additional lesions. The limitation of NBI is high false-positivity and its availability. Long-term follow-up studies with a larger subset of patients are required to evaluate its role in decreasing recurrences and justification in routine clinical practice.
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There are no conflicts of interest. by radiotherapy. She was started adjuvant tamoxifen 20 mg once daily. Three years later in August 2010, she presented with hepatomegaly and deranged liver function tests (LFTs) with aspartate transaminase and alanine transaminase were 114 and 67 U/L, respectively and radiology suspicious of liver metastasis [ Figure 1 ]. Tamoxifen was thus stopped. The patient, however, defaulted at this time. When she returned 6 months later, her hepatomegaly had reduced and liver function improved. Thus, tamoxifen-induced liver injury was suspected and proven on liver biopsy, which revealed portal fibrosis with portoportal bridging fibrosis and ballooning degeneration with steatohepatitis [ Figure 2 ]. She was then started on letrozole. Her LFT remained normal. She had a locoregional recurrence after 4 years in June 2014, for which she underwent wide local excision and palliative radiotherapy and letrozole was changed to exemestane with no deterioration in LFT. In September 2017, she again had a second locoregional recurrence and exemestane was changed to fulvestrant. Within 4 months, however, she had worsening of LFT. Subsequent imaging did not reveal any metastasis. Fulvestrant was stopped because of suspected drug-induced liver injury and letrozole was restarted. Her LFT, however, progressively deteriorated and that careful, COE of the entire oral cavity on a regular basis remains the gold standard for early detection of OPMD.
Farah et al. [5] conducted a study in which he concluded that the combination of COE and VELscope is more beneficial in identifying the dysplastic changes when compared to only COE or VELscope (diascopic fluorescence) and only the VELscope examination may not be useful.
The efficacy of a diagnostic test is dependent on its sensitivity and specificity values. Overall, seven studies out of eleven have shown the sensitivity values >0.70 and with varied specificity values.
Conclusion
Identifying the oral lesions before transforming to neoplasia is important to increase the survival rate of the patient and for a good prognosis. However, only COE may not be sufficient to detect the lesions in the early stages, and hence, the new adjunct techniques may help the clinicians to detect the dysplastic changes initially and stop further progression of the disease to the OSCC. Autofluorescence using devices may be used as adjunct to find the exact location of the biopsy in altered mucosal conditions. Due to high FPRs the use of these devices is limited. However, the COE followed by biopsy of the lesion will remain the gold standard of the detection of the lesions.
she developed cirrhosis with ascites and portal hypertension with small esophageal varies. Other causes of cirrhosis (autoimmune profile, viral serology, and nonalcoholic fatty liver diseases) were excluded. Thus, the patient had progressive liver dysfunction, leading to significant morbidity. This is an unusual case where the patient had tamoxifen-induced steatohepatitis, which resolved after stopping tamoxifen and recurred after starting fulvestrant several years later, subsequently progressing to cirrhosis and liver failure.
Tamoxifen causes increased de novo fatty acid synthesis and inhibition of mitochondrial fatty acid β-oxidation in the liver, subsequently leading to macrovacuolar steatosis. This risk increased with concomitant obesity, type II diabetes, and (Letter to the editor continue from page 228...) metabolic syndrome. Fulvestrant's hepatotoxicity is possibly caused by its immunogenic metabolite. In postmenopausal women, aromatase inhibitors displayed less fatty liver disease compared to tamoxifen or fulvestrant, suggesting a more favorable hepatic safety profile.
In conclusion, this is a rare case of steatohepatitis and later cirrhosis induced by antiestrogenic therapy. As this can at times masquerade as metastasis, it may be important to biopsy doubtful cases, especially if liver functions improve after stopping the drug. Thus, physicians should be alert to the possibility of drug-induced liver injury with both tamoxifen and fulvestrant.
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Letter to the Editor
Metachronous muscle metastasis in a case of metastatic gallbladder cancer with TP35 gene mutation: A rare case report DOI: 10.4103/sajc.sajc_139_19
Dear Editor, Gallbladder carcinoma (GBCA) is the most common and aggressive type of biliary tract cancer. Surgery offers the only chance of cure. However, only 10% of patients have resectable disease at presentation. [1] The spread modes of GBCA are direct, lymphatic, vascular, neural, intraperitoneal, and intraductal. Liver and lymph nodes are the two most common sites of metastasis of GBCA. [2, 3] Metastasis to other organs such as bone and lung is very uncommon. [4] Here, we present a case of GBCA who developed muscle metastasis twice during his treatment. This is an extremely rare finding, and only a single case report exists before this publication. [5] In January 2018, a 55-year-old male, hypertensive, presented to us with the complaints of right upper quadrant abdominal pain for 2 months. He also had a weight loss of 10 kg in the last 3 months. Ultrasound of the abdomen showed a gallbladder lesion of size 6.3 cm × 6.1 cm in the right lobe of the liver close to gallbladder fossa. He was evaluated at our center with a contrast-enhanced magnetic resonance imaging (MRI) scan of the upper abdomen, which showed a mass in segment 4a/4b/5 of 
